Quince Therapeutics (QNCX) Retained Earnings (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Retained Earnings of $435.6 million for Q1 2026, up 211.26% year-over-year from $139.9 million in Q1 2025, and up 3.96% quarter-over-quarter from $419.0 million in Q4 2025.
Quince Therapeutics (QNCX) Retained Earnings (2018 - 2026) Analysis & Trends
Quince Therapeutics' Retained Earnings history runs 9 years deep, the most recent figure standing at $435.6 million for Q1 2026.
- In Q1 2026, Retained Earnings rose 211.26% year-over-year to $435.6 million; the TTM figure through Mar 2026 stood at $435.6 million (up 211.26% YoY), while the FY2025 annual figure was $419.0 million, up 211.29% from the prior year.
- Retained Earnings for Q1 2026 stood at $435.6 million, up from $419.0 million in the prior quarter.
- The five-year high for Retained Earnings was $435.6 million in Q1 2026, with the low at -$407.6 million in Q2 2025.
- The 5-year median for Retained Earnings is -$466000.0 (2022), against an average of -$93.6 million.
- Peak annual rise in Retained Earnings reached 1154.33% in 2023, while the deepest fall reached 122745.85% in 2023.
- Quince Therapeutics' Retained Earnings stood at -$289000.0 in 2022, then soared by 1154.33% to $3.0 million in 2023, then plunged by 12455.5% to -$376.5 million in 2024, then surged by 211.29% to $419.0 million in 2025, then increased by 3.96% to $435.6 million in 2026.
- Business Quant data shows QNCX's Retained Earnings at $435.6 million in Q1 2026, $419.0 million in Q4 2025, and $6.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | -500.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 435.59 Mn |
| Dec 31, 2025 | 418.98 Mn |
| Sep 30, 2025 | 6.29 Mn |
| Jun 30, 2025 | -407.55 Mn |
| Mar 31, 2025 | -391.50 Mn |
| Dec 31, 2024 | -376.47 Mn |
| Sep 30, 2024 | -364.01 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 1.83 Mn |
| Dec 31, 2023 | 3.05 Mn |
| Sep 30, 2023 | -310.80 Mn |
| Jun 30, 2023 | -305.40 Mn |
| Mar 31, 2023 | -300.50 Mn |
| Dec 31, 2022 | -289,000.00 |
| Sep 30, 2022 | -253,000.00 |
| Jun 30, 2022 | -466,000.00 |
| Mar 31, 2022 | -506,000.00 |
| Dec 31, 2021 | -236.60 Mn |
| Sep 30, 2021 | 71,000.00 |
| Jun 30, 2021 | 117,000.00 |